Dopamine Articles & Analysis
20 news found
These APIs are mostly regulators of neurotransmitters such as dopamine and serotonin, which are central to mental stability. These range from conventional drugs such as chlorpromazine and haloperidol, to noveler ones such as aripiprazole. ...
Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. While stimulants are the gold-standard of ADHD treatment due to their efficacy and safety, the long-standing challenge remains, providing patients entire active-day duration of action. ...
Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. While stimulants are the gold-standard of ADHD treatment due to their efficacy and safety, the long-standing challenge remains, providing patients entire active-day duration of action. ...
Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect attention and behavior. While stimulants are the gold-standard of ADHD treatment due to their efficacy and safety, the long-standing challenge remains, providing patients entire active-day duration of action. ...
This study is now complete and analytical results are expected to be finalized and announced within the coming days. Rotigotine is a non-ergoline dopamine agonist approved for the treatment of Parkinson’s disease and restless legs syndrome (RLS) in Europe and the United States. ...
PD is a chronic and progressive neurodegenerative disorder that affects predominately dopamine-producing (“dopaminergic”) neurons in the substantia nigra area of the brain. ...
ByVaxxinit
Betahistine is known to increase the release of histamine, acetylcholine, dopamine and norepinephrine in the brain. It increases cochlear, vestibular and cerebral blood flow and facilitates vestibular compensation and inhibits neuronal firing in the vestibular nuclei. ...
About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. The worsening of motor and non-motor symptoms is caused by the loss of dopamine-producing neurons. ...
About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. The worsening of motor and non-motor symptoms is caused by the loss of dopamine-producing neurons. ...
About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. The worsening of motor and non-motor symptoms is caused by the loss of dopamine-producing neurons. ...
In this study, subjects undergo surgical transplantation of the dopamine-producing cells into the putamen. The first surgery was performed by Dr. ...
About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. The worsening of motor and non-motor symptoms is caused by the loss of dopamine-producing neurons. ...
“This is a big step for the stem cell field – to finally test a truly “off-the-shelf” dopamine neuron product in human PD patients,” said Lorenz Studer, MD, scientific co-founder of BlueRock and Director, Center for Stem Cell Biology at MSK. ...
The therapy is designed to restore the balance of key neurotransmitters in the brain – dopamine, serotonin and norepinephrine – that are known to regulate sexual inhibition and sexual excitation. ...
Currently, treatment options are limited with only one drug, metoclopramide (brand name Reglan®), a four times daily oral dopamine D2 receptor antagonist, approved for the treatment of gastroparesis; however, treatment with metoclopramide for more than 12 weeks should be avoided due to the risk of tardive dyskinesia. ...
The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc's randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw's chronic drug delivery system, in Parkinson's patients. ...
Currently, only one drug, metoclopramide (brand name Reglan®) a dopamine D2 receptor antagonist, is approved for the treatment of gastroparesis. ...
It has a unique mechanism of action designed to restore the balance of three neurotransmitters – dopamine, serotonin and norepinephrine – that are known to regulate sexual inhibition and sexual excitation. ...
GDNF might be able to restore function of degenerating dopamine-producing-cells and thus retard progression of the disease and even reverse the course of the disease. ...
The COMT enzyme, well known for its role in dopamine degradation, is activated during early neurodevelopment. Structural and functional brain differences have been described across COMT genotypes, particularly in the hippocampal and prefrontal cortex, regions affected by autism. ...